Ultimovacs - Phase II data from 500+ patients over 2022/23
Ultimovacs’ R&D pipeline has been transformed over the past few weeks. Although delayed by the pandemic, the company has delivered on its promise to initiate a third Phase II trial (UV1 durvalumab and olaparib in ovarian cancer) led by investigators, with combination drugs supplied by AstraZeneca. The recent surprise was, however, the fourth Phase II trial (UV1 plus pembrolizumab in head and neck cancer). Ultimovacs is sponsoring its flagship INITIUM trial (UV1 plus ipilimumab and nivolumab in melanoma), while the other three are led by investigators that are top European oncology organisations. So, in our view, it is the ability to forge relationships with different stakeholders that allowed such an expansion of the pipeline and will ensure eventful years in 2022 and 2023.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.